Aeroswiss Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.50 M
- Revenue Growth 892.19%
- Profit Growth 324.45%
- Ebitda -33.90%
- Net Worth 55.43%
- Total Assets 154.61%
About Aeroswiss Biotech
Aeroswiss Biotech Private Limited (ABPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 July 2020 (Four years and seven months 6 days old ). Its registered office is in Raebareli, Uttar Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.50 M.
Satendra Singh and Sachin Singh serve as directors at the Company.
Company Details
- Location
Raebareli, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100UP2020PTC131292
- Company No.
131292
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jul 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Aeroswiss Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satendra Singh  | Director | 20-Jul-2020 | Current |
| Sachin Singh | Director | 20-Jul-2020 | Current |
Financial Performance of Aeroswiss Biotech.
Aeroswiss Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 892.19% increase. The company also saw a substantial improvement in profitability, with a 324.45% increase in profit. The company's net worth Soared by an impressive increase of 55.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aeroswiss Biotech?
Unlock access to Aeroswiss Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹1.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Sep 2021 | Others | ₹1.50 M | Open |
How Many Employees Work at Aeroswiss Biotech?
Aeroswiss Biotech has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aeroswiss Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aeroswiss Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
